Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

RxSight (RXST) Operating Expenses (2020 - 2025)

Historic Operating Expenses for RxSight (RXST) over the last 6 years, with Q3 2025 value amounting to $36.4 million.

  • RxSight's Operating Expenses rose 568.72% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.0 million, marking a year-over-year increase of 1980.22%. This contributed to the annual value of $135.8 million for FY2024, which is 3076.65% up from last year.
  • Per RxSight's latest filing, its Operating Expenses stood at $36.4 million for Q3 2025, which was up 568.72% from $39.2 million recorded in Q2 2025.
  • Over the past 5 years, RxSight's Operating Expenses peaked at $39.2 million during Q2 2025, and registered a low of $12.3 million during Q1 2021.
  • Its 5-year average for Operating Expenses is $26.1 million, with a median of $25.6 million in 2023.
  • As far as peak fluctuations go, RxSight's Operating Expenses surged by 8107.83% in 2021, and later surged by 568.72% in 2025.
  • Over the past 5 years, RxSight's Operating Expenses (Quarter) stood at $17.5 million in 2021, then rose by 27.83% to $22.4 million in 2022, then increased by 27.19% to $28.5 million in 2023, then skyrocketed by 31.26% to $37.4 million in 2024, then decreased by 2.7% to $36.4 million in 2025.
  • Its Operating Expenses was $36.4 million in Q3 2025, compared to $39.2 million in Q2 2025 and $39.0 million in Q1 2025.